Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Sipatrigine is a neuroprotective agent and derivative of lamotrigine (Item No. 15428).1 It inhibits neuronal voltage-gated sodium and calcium channels in a voltage-dependent manner. Sipatrigine reduces the neuronal firing frequency and decreases the amplitude of excitatory post-synaptic potentials (EPSPs) in electrically stimulated rat corticostriatal slices (EC50s = 4.5 and 2 µM, respectively).2 It inhibits veratrine-induced glutamate and aspartate release in rat cerebral cortex slices (IC50s = ~5 µM for both).3 Sipatrigine (30 mg/kg, i.v.) reduces infarct volume in a rat model of focal ischemia induced by middle cerebral artery occlusion (MCAO).4
WARNING This product is not for human or veterinary use.
1. Sipatrigine (BW 619C89) is a neuroprotective agent and a sodium channel and calcium channel inhibitor. CNS Drug Rev. 6(2), 111-134 (2000).
2. Electrophysiology of sipatrigine: A lamotrigine derivative exhibiting neuroprotective effects. Exp. Neurol. 162(1), 171-179 (2000).
3. BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage. Stroke 24(7), 1063-1067 (1993).
4. Neuroprotective effects of a use-